A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients

This study has been completed.
Sponsor:
Collaborator:
The Hong Kong Society of Nephrology
Information provided by:
Hospital Authority, Hong Kong
ClinicalTrials.gov Identifier:
NCT00563355
First received: November 21, 2007
Last updated: June 14, 2011
Last verified: June 2011

November 21, 2007
June 14, 2011
February 2001
Not Provided
  • endothelial function and atherosclerosis [ Time Frame: 6 month, 1 year ]
  • cardiac hypertrophy and cardiac function [ Time Frame: 6 month, 1 year ]
Same as current
Complete list of historical versions of study NCT00563355 on ClinicalTrials.gov Archive Site
  • nutrition status [ Time Frame: 6 month, 1 year ]
  • residual renal function [ Time Frame: 6 month, 1 year ]
  • quality of life [ Time Frame: 6 month, 1 year ]
Same as current
Not Provided
Not Provided
 
A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients
A Prospective Randomised Controlled Trial to Study the Effects of Recombinant Human Erythropoietin on the Progression of Atherosclerosis, Cardiovascular Function, Nutrition and Residual Renal Function in Pre-dialysis Chronic Renal Failure Patients

The primary aim of the study is to evaluate the effects of correction of anemia using erythropoietin on the progression of atherosclerosis and cardiac muscle thickening in patients with chronic kidney disease

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Chronic Disease
  • Kidney Diseases
  • Cardiovascular Diseases
Drug: erythropoietin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
66
November 2003
Not Provided

Inclusion Criteria:

  • Patients with chronic renal failure with serum creatinine between 150umol/L and 800umol/L and at the same time Hb
  • Patients with regression line of 1/serum creatinine versus time showing that they may not require dialysis within the coming 12 months
  • Patients below the age of 75

Exclusion Criteria:

  • Patients with valvular heart disease/congenital heart disease
  • Patients with ischemic heart disease/history of myocardial infarction/coronary artery bypass surgery
  • Patients with history of heart failure
  • Patients with regression line of 1/serum creatinine versus time showing that the estimated date of end stage renal disease is within 12 months
  • Patients with thalassemic trait or haemoglobinopathies
  • Patients with underlying haematological malignancies
  • Patients with active bleeding
  • Patients with uncorrected iron or other vitamins deficiencies
  • Patients with poor general condition
Both
up to 75 Years
Not Provided
Contact information is only displayed when the study is recruiting subjects
China
 
NCT00563355
CRE2000.241, HARECCTR0500004
Not Provided
Not Provided
Hospital Authority, Hong Kong
The Hong Kong Society of Nephrology
Principal Investigator: Angela YM Wang, Dr Department of Medicine & Therapeutics/Nephrology, Prince of Wales Hospital/ The Chinese University of Hong Kong
Hospital Authority, Hong Kong
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP